Filling the Future:
Latest Developments in Fill/Finish Capabilities Across APAC
10 - 11 September 2025 | Sheraton Towers Singapore
Fill/finish is a critical step in biopharmaceutical manufacturing, ensuring sterility, safety and readiness for patient use. Across Asia-Pacific, rising demand for biologics is accelerating investment and innovation in fill/finish infrastructure. This eBook highlights the latest regional advancements, facility expansions and technology upgrades in key APAC markets, showcasing how manufacturers are scaling up to meet global needs for sterile drug product delivery.
Country: South Korea
Launch of Bio Campus II & Sixth Plant
Samsung Biologics expanded its Songdo, South Korea site with the launch of Plant 5 (180,000 L capacity) and announced construction plans for a Plant 6, boosting its total capacity to 964,000 L. This includes new aseptic fill/finish capabilities such as pre-filled syringe lines slated for 2027.
Country: Singapore
Fully Automated Aseptic Fill/Finish Plant
Thermo Fisher opened a high-speed, fully automated aseptic fill/finish plant in Singapore, designed for both small and large molecules (including vaccines). It’s located in Joo Koon Circle in the Jurong district and reported by the Economic Development Board (EDB) in 2020 to have cost US$130 million (S$175 million).
https://www.straitstimes.com/singapore/new-thermo-fisher-scientific-drug-facility-for-vaccine-manufacture-opens-in-singapore
Country: Australia
SA25 GMP Filling Line
NovaCina expanded its Perth facility in late 2024, installing a robotic SA25 GMP filling line for vials, pre-filled syringes and cartridges. The new filling line will be compliant with Annex 1 guidelines for the manufacture of sterile medicinal products, issued by the European Union. The batch sizes can range from 0.5 L to 500 L, and accommodate fill volumes from 0.5 mL to 30 mL for glass vials and PFS.
Country: China
Fill/Finish Capacity Expansion
WuXi Biologics’ Hangzhou facility will expand from 8,000 L to 23,000 L capacity. The 50,000 m² site includes vial filling and pre-filled syringe capabilities, boosting its overall fill/finish capacity to meet rising global demand.
Country: Japan
Collaboration to Expand Combined Fill/Finish Capacity
Takeda partnered with Fujifilm to expand their combined fill-finish capacity for biologics in Japan, reflecting growing demand for flexible aseptic manufacturing.
These developments are not only transforming the regional fill/finish ecosystem but also underscoring Asia’s readiness to serve global markets with quality and speed. To explore these trends and more, we invite you to join Biologics CDMO Asia (BCDMOA) 2025, taking place on 10–11 September 2025 at Sheraton Towers Singapore. This premier gathering brings together industry players to discuss the future of contract manufacturing in Asia. Don’t miss the opportunity to engage with industry pioneers and shape the next chapter in biologics manufacturing.
For deeper engagement, join us at BCDMOA 2025 in Singapore, where collaboration and innovation shape the future of biologics manufacturing.
BIOLOGICS CDMO ASIA 2025
Asia's Premier Event Exclusively for CDMO's!
📍Sheraton Towers Singapore 📆 10 - 11 September 2025
The 4th Biologics CDMO Asia 2025 is a prominent event that brings together key leaders in the contract manufacturing sector to exchange successful case studies, address challenges and opportunities, and explore potential partnerships. It is also the only conference in the region that is exclusively focused on Contract Manufacturing in the APAC region.
350+ Attendees
180+ Organisations
40+ Expert Speakers
2025 SPEAKERS
Share With Your Network
